Martin Achleitner

596 total citations
8 papers, 382 citations indexed

About

Martin Achleitner is a scholar working on Molecular Biology, Immunology and Neurology. According to data from OpenAlex, Martin Achleitner has authored 8 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Immunology and 3 papers in Neurology. Recurrent topics in Martin Achleitner's work include interferon and immune responses (4 papers), Long-Term Effects of COVID-19 (3 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers). Martin Achleitner is often cited by papers focused on interferon and immune responses (4 papers), Long-Term Effects of COVID-19 (3 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers). Martin Achleitner collaborates with scholars based in Germany, United Kingdom and Switzerland. Martin Achleitner's co-authors include Axel Roers, Rayk Behrendt, Ronald Naumann, Silke Glage, Katrin Peschke, Stefan R. Bornstein, Waldemar Kanczkowski, Alexander Gerbaulet, Roman N. Rodionov and Julio Licínio and has published in prestigious journals such as The Journal of Experimental Medicine, The Journal of Immunology and Molecular Psychiatry.

In The Last Decade

Martin Achleitner

7 papers receiving 379 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martin Achleitner Germany	5	234	167	58	47	45	8	382
Caterina E. Faliti United States	7	144 0.6×	258 1.5×	11 0.2×	46 1.0×	70 1.6×	10	462
Björn Ryberg Sweden	10	67 0.3×	76 0.5×	86 1.5×	18 0.4×	34 0.8×	27	282
Linda M. Dallasta United States	5	113 0.5×	69 0.4×	22 0.4×	49 1.0×	50 1.1×	5	428
Peter Dias United States	10	140 0.6×	161 1.0×	7 0.1×	35 0.7×	40 0.9×	16	392
Ivan Osokine United States	8	75 0.3×	279 1.7×	5 0.1×	99 2.1×	34 0.8×	8	392
Keinosuke Fujita Japan	11	146 0.6×	24 0.1×	18 0.3×	12 0.3×	33 0.7×	24	368
Natalia Guerra‐Pérez Spain	11	95 0.4×	130 0.8×	5 0.1×	43 0.9×	28 0.6×	18	367
Julia Albrecht Germany	8	128 0.5×	227 1.4×	6 0.1×	140 3.0×	20 0.4×	11	457
Joan O’Keeffe Ireland	11	68 0.3×	207 1.2×	9 0.2×	24 0.5×	8 0.2×	17	360
Christophe Capelle Luxembourg	5	74 0.3×	110 0.7×	9 0.2×	65 1.4×	24 0.5×	8	189

Countries citing papers authored by Martin Achleitner

Since Specialization

Citations

This map shows the geographic impact of Martin Achleitner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Achleitner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Achleitner more than expected).

Fields of papers citing papers by Martin Achleitner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Achleitner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Achleitner. The network helps show where Martin Achleitner may publish in the future.

Co-authorship network of co-authors of Martin Achleitner

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Achleitner. A scholar is included among the top collaborators of Martin Achleitner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Achleitner. Martin Achleitner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Achleitner, Martin, Oliver Tiebel, Nicolai Leuchten, & Martin Aringer. (2025). Interleukin-6 receptor blockade leads to low fibrinogen values as part of their effects on the acute phase. Lara D. Veeken. 64(8). 4842–4843.

Achleitner, Martin, Milo A. Puhan, Irène A. Abela, et al.. (2023). Absence of Type I Interferon Autoantibodies or Significant Interferon Signature Alterations in Adults With Post–COVID-19 Syndrome. Open Forum Infectious Diseases. 11(1). ofad641–ofad641. 4 indexed citations

Achleitner, Martin, Charlotte Steenblock, Natalia Jarzebska, et al.. (2023). Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis. Molecular Psychiatry. 28(7). 2872–2877. 31 indexed citations

Bornstein, Stefan R., Roman N. Rodionov, Raul R. Gainetdinov, et al.. (2021). Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Molecular Psychiatry. 27(1). 34–37. 56 indexed citations

Achleitner, Martin, Alexander Hennig, Katrin Peschke, et al.. (2017). Lack of Trex1 Causes Systemic Autoimmunity despite the Presence of Antiretroviral Drugs. The Journal of Immunology. 199(7). 2261–2269. 33 indexed citations

Peschke, Katrin, Martin Achleitner, Kathrin Frenzel, et al.. (2016). Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity. The Journal of Immunology. 197(6). 2157–2166. 69 indexed citations

Peschke, Katrin, Kathrin Frenzel, Martin Achleitner, et al.. (2015). Tracing cellular sources of pathogenic type I-interferon in the TREX1-/- mouse model of lupus like-disease. Pediatric Rheumatology. 13(S1). 1 indexed citations

Achleitner, Martin, et al.. (2012). Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. The Journal of Experimental Medicine. 209(8). 1419–1426. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact